Blood Cancer

Biography

Thomas Mehrling MD, PhD is Chief Executive Officer of the 2013 founded Mundipharma EDO GmbH in Basel, Switzerland. The company is part of the independent associated companies of the Mundipharma Group. The company is developing a number of early stage oncology assets, small molecules and biologics, through pre-clinical and clinical research. The first compound EDO-S101 has rapidly progressed through the pre-clinical development stage and is now investigated in Phase 1 clinical studies. He is a board certified pharmacist/pharmacologist and obtained his PhD in pharmacological science based on pre-clinical research in serotonin-receptor antagonists for the treatment of nausea and vomiting caused by chemotherapy. This work provided the pathway to the market for tropisetron (Navoban®). He also is a board certified physician and holds a medical doctor degree of the University of Frankfurt. He specialized and worked for several years in cardiology, hematology/oncology and pediatric oncology. Research during the time at the University focused on clinical research through small and large trials, mechanisms of multi drug resistance in cancer cells as well as the diagnosis of hematological malignancies. After years of practice at the University hospital and in a private oncology practice he joined in 1997 the Takeda Research & Development Centre Europe where he was responsible for the pan-European development of 3 new chemical entities in a global development team working from Japan across Europe and the Untied States. From there he moved to a Global CRO where he held the position of a Vice President Medical and Regulatory Affairs before he joined the Mundipharma Group in the year 2000. Since this time he went through various positions at Mundipharma starting with being responsible for the in-licensing of a first hematology/oncology product to found this new business and then to take on responsibility to develop, register and launch oncology products to the markets. Today, the Mundipharma Group is marketing DepoCyte® and bendamustine (Levact®, Ribomustin®, Treanda®) in Europe. Forodesine, the first selective PNP inhibitor for treating cancer in a variety of hematological malignancies is submitted to the Japanese authorities. In the Asian companies Mundipharma is also distributing Folotyn and Zevalin in selected markets. He is a member of AACR, ASCO and ASH as well as EMSO and EHA and lives in Basel where he enjoys the culture and atmosphere of the city.

Research Interest

Pre-clinical research, Chemotherapy, Hematology/oncology, Cancer cells, Hematological malignancies